- Lobbying
- aventis AND pharmaceuticals
Lobbying Arrangements Results for 'Aventis Pharmaceuticals'
Former Covered Federal Workers:
Other Lobbyists:
Issue | Client | Firm | Lobbyists | Start Date | Latest Filing Date |
---|---|---|---|---|---|
Details Medicare. |
Sanofi US Services Inc f/k/a sanofi-aventis U.S. Inc.
|
Hogan Lovells US LLP | |||
Details issues in PPACA, health reform that might impact pharmaceuticals and veterans health care |
Sanofi-Aventis, US, Inc.
|
McKenna Long & Aldridge LLP | |||
Details Patient Protection and Affordable Care Act - H.R.3590 Affordable Health Care for America Act - HR 3962; Follow-on Biologics - H.R.1427, H.R.1548 |
Sanofi-aventis U.S., Inc.
discover, develops and markets prescription pharmaceuticals |
FOLEY HOAG LLP | |||
Details FDA related issues; DTC advertizing follow on biologics-(biosimilars); Health care reform issues as they relate to pharmaceutical industry in general and sanofi-aventis in particular Manufacturing ... |
sanofi-aventis U.S. Inc.
|
PrO Unlimited | |||
Details Monitored consideration of patent legislation; international intellectual property issues; general issues related to patent settlements; and all provisions of H.R. 9, the Innovation Act. General is... |
Sanofi US Services Inc. (formerly known as sanofi-aventis U.S. Inc.)
|
PARRY, ROMANI, DECONCINI & SYMMS | |||
Details Issues related to corporate tax reform and extension of the R&D tax credit. Issues related to pharmaceutical reimbursement; Issues related to the expansion of Medicaid drug rebate; Issues related t... |
SANOFI-AVENTIS U.S. Inc.
|
RICCHETTI INCORPORATED | |||
Details Corporate tax reform; all provisions of HR 4718 "To amend the Internal Revenue Code of 1986 to modify and make permanent bonus depreciation," a strengthened and permanent U.S. R&D tax credit, inclu... |
Sanofi US Services Inc. (Formerly known as sanofi-aventis U.S. Inc.)
|
CANFIELD & ASSOCIATES, INC. | |||
Details Education and awareness of the 2013-2014 influenza season; education and awareness of pandemic and biodefense funding; education and awareness of Dengue; general issues related to FDA and NIH fund... |
Sanofi US Services Inc. (Formerly known as sanofi-aventis U.S. Inc.)
|
TCH Group, LLC | |||
Details DOJ policy regarding off label communications. |
Medical Information Working Group
|
SIDLEY AUSTIN LLP | |||
Details Issues related to prescription-to- over the counter switch; issues related to influenza vaccines; issues related to 340B; issues related to Respiratory Syncytial Virus (RSV) access; issues related ... |
Sanofi US Services Inc.
|
in-house lobbying | |||
Details Enforcement priorities and policies regarding communications by pharmaceutical and medical device manufacturers about their medical products. |
Medical Information Working Group
|
Ropes & Gray, LLP | |||
Details Health care reform; drug safety, value and reimbursement; prevention, diagnosis and treatment of chronic disease; implementation of related provisions in the Affordable Care Act; value of prescript... |
Sanofi US Services Inc.
|
Capitol Counsel LLC |